Thelansis

Non-Small Cell Lung Cancer (NSCLC) Emerging Therapy and TPP Insights Thelansis’s “Non-Small Cell Lung Cancer (NSCLC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Non-Small Cell Lung Cancer (NSCLC) Overview Non-small cell lung cancer (NSCLC) is the predominant form of lung cancer, accounting for approximately 85% of all cases. Around 15–20% are diagnosed at an early stage, where surgical resection, often combined with adjuvant chemotherapy or radiotherapy, offers the best chance of cure. Risk factors can be divided into modifiable and non‑modifiable categories. Modifiable risks include tobacco smoking, secondhand smoke, and occupational or environmental exposures such as asbestos, radon, arsenic, chromium, nickel, ionizing radiation, ...

Non-Small Cell Lung Cancer (NSCLC) Emerging Therapy and TPP Insights Thelansis’s “Non-Small Cell Lung Cancer (NSCLC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication . Key business questions answered: Detailed emerging competitive landscape Pipeline analysis Target patients for emerging therapies Key companies Key mechanism of actions Launch date estimates, etc. Clinical trial landscape analysis Target patient segments Trial endpoints Trial design Recruitment criteria, etc. Unmet Needs and Opportunities Performance of key current therapies Top areas of unmet needs Opportunity sizing for key unmet needs Targ...